GILEAD SCIENCES, INC. is 72.5x more valuable than BIOCRYST PHARMACEUTICALS INC by market capitalization ($150.83 B vs $2.08 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BCRX | GILD |
|---|---|---|
| Market cap | $2.08 B | $150.83 B |
| US-listed rank | #2072 | #99 |
| Revenue (latest FY) | $874.84M | $29.44B |
| Net income (latest FY) | $263.86M | $8.51B |
| Net margin | 30.2% | 28.9% |
| P/E (trailing FY) | 7.9 | 17.7 |
| SEC filings | 1,935 | 981 |
GILEAD SCIENCES, INC. is 72.5x more valuable than BIOCRYST PHARMACEUTICALS INC by market capitalization ($150.83 B vs $2.08 B).
In their latest fiscal years, BIOCRYST PHARMACEUTICALS INC reported $874.84M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: BIOCRYST PHARMACEUTICALS INC and GILEAD SCIENCES, INC., or browse the full rankings.